Newcastle University
Toggle Main Menu
Toggle Search
Home
Browse
Latest
Stats
Policies
About
Home
Browse
Latest
Policies
About
ePrints
Browse by author
Browsing publications by
Dr Miranda Morton.
Newcastle Authors
Title
Year
Full text
Dr Arthur Pratt
Dr Stefan Siebert
Mike Cole
Dr Deborah Stocken
Amy Cranston
et al.
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial
2021
Dr Stefan Siebert
Dr Arthur Pratt
Dr Deborah Stocken
Dr Miranda Morton
Amy Cranston
et al.
Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial
2020
Dr Emma Clark
Dr Miranda Morton
Shriya Sharma
Dr Holly Fisher
Denise Howel
et al.
Prostate cancer androgen receptor splice variant 7 biomarker study - A multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol
2019
Dr Ashleigh Herriott
Dr Miranda Morton
Professor Nicola Curtin
Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline
BRCA1/2
mutations and selected sporadic cancers
2017
Iaroslava Kos
Dr Miranda Morton
Alessandra da Silva Dantas
Professor Janet Quinn
Mechanisms underlying the delayed activation of the Cap1 transcription factor in
Candida albicans
following combinatorial oxidative and cationic stress important for phagocytic potency
2016
Dr Alastair Greystoke
Dr Linda Hogarth
Dr Miranda Morton
Liam Bolt
Dianne Turner
et al.
The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained
2016
Fiona Middleton
Dr Miranda Morton
Dr Claire Elstob
Dr Sarah Fordham
Dr Ashleigh Herriott
et al.
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition
2015
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Morton
et al.
PARP1 expression, activity and
ex vivo
sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia
2015
Dr Miranda Morton
Dr Ian Forrest
Becci Sharrock
Maria Lane
Dr Angelika Kaufmann
et al.
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
2014
Dr Miranda Morton
Professor Janet Quinn
Mechanisms Underlying the Exquisite Sensitivity of
Candida albicans
to Combinatorial Cationic and Oxidative Stress That Enhances the Potent Fungicidal Activity of Phagocytes
2014
James Murray
Huw Thomas
Phil Berry
Suzanne Kyle
Dr Miranda Morton
et al.
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
2014
Dr Miranda Morton
Professor Nicola Curtin
Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies
2013
Dr Miranda Morton
Alessandra da Silva Dantas
Dr Elizabeth Veal
Professor Brian Morgan
Professor Janet Quinn
et al.
Ybp1 and Gpx3 Signaling in
Candida albicans
Govern Hydrogen Peroxide-Induced Oxidation of the Cap1 Transcription Factor and Macrophage Escape
2013
Dr Miranda Morton
Professor Janet Quinn
Impact of combinatorial stresses upon
Candida albicans
2012
Dr Miranda Morton
James Murray
Professor Nicola Curtin
Stability of PARP Inhibition by BMN 673 in Human PBMCs (and Leukaemic Cell Cultures)
2012
Alessandra da Silva Dantas
Dr Miranda Morton
Professor Brian Morgan
Professor Janet Quinn
Thioredoxin regulates multiple hydrogen peroxide-induced signaling pathways in
Candida albicans
2010
Jill Cheetham
Alessandra da Silva Dantas
Dr Miranda Morton
Dr Catherine Bruce
Professor Janet Quinn
et al.
A single MAPKKK regulates the Hog1 MAPK pathway in the pathogenic fungus
Candida albicans
2007